Anti-PD1 immunotherapy pembrolizumab (KEYTRUDA®) has been registered by the TGA
20 April 2015
MSD announced that its anti-PD1 immunotherapy pembrolizumab (trade name KEYTRUDA®) has been registered by the Therapeutic Goods Administration (TGA) for the treatment of the most deadly form of skin cancer – advanced metastatic melanoma. Australia is the first country in the world to register KEYTRUDA for the first line treatment of unresectable or metastatic melanoma in adults. This will change the future of treatments for all melanoma patients in Australia.
Associate Professor Georgina Long from Melanoma Institute of Australia (MIA) explained that Australian clinicians and institutes have been involved in the clinical trials of anti-PD1 for over three years.
“We are proud to have been involved in the development of this medicine and that hundreds of Australian patients with advanced melanoma have been treated with pembrolizumab. This drug is being investigated for use in other cancers. It is vital we continue to do research such as this to improve the outcomes for cancer patients.”
MIA and affiliates will continue to lobby on behalf of the Australian community to ensure anti-PD1 is added to the PBS which would make it accessible for all Australians with advanced melanoma without delay.
Melanoma patients across Australia will benefit from the release of updated clinical care guidelines.
An American study has discovered a link between early detection and marital status in melanoma diagnosis.
An international course on melanoma pathology in Paris, France co-directed by Professor Richard Scolyer took place over the weekend.
Professor Richard Scolyer highlights the difficulties of diagnosis following the Australian Story feature program on Emma Betts.
Cancer Australia releases 'stage at diagnosis' data for top five incidence cancers – including melanoma
For the first time in Australia, national data has been released on cancer stage at diagnosis. This data explores the top five incidence cancers – female breast cancer, colorectal, lung, prostate cancers and melanoma.
'Dear Emma' - a tribute to the life and times of a young woman determined to raise awareness about melanoma.
Carole Renouf, CEO for MIA thanks Toyota for helping fuel ongoing melanoma research.
Fraser Dykes tackled the Kokoda Trail on an eight day trek in memory of his friend Mark 'Bod' Boddison.
Harvard’s Clinical Professor Martin Mihm and MIA’s Conjoint Medical Director Professor Richard Scoyler delivered a series of lectures on melanoma pathology in Vancouver, British Colombia this week at the world’s biggest annual pathology meeting.
A round of applause for a well deserved win.
A message from our CEO, Carole Renouf
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.
Melanoma Institute Australia's annual fundraising initiative is all systems go!
The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.